House panel blames FDA for drug shortages

Share this article:
Darrell Issa
Darrell Issa

A new report from the House Committee on Oversight and Government Reform blames FDA for shortages of generic injectable medications.

Chairman Darrell Issa (R-CA) says a committee investigation learned that FDA regulatory activity has effectively shut down 30% of manufacturing capacity at four of the largest US producers of generic injectable drugs.

Issa says FDA commissioner Margaret Hamburg and the agency have failed to ensure that its enforcement methods avoid “unnecessary shortages.”

The report notes that between 2010 and 2011, there was a 156% increase in FDA Warning Letters. “Warning letters have resulted in companies agreeing to take manufacturing off-line to address FDA criticisms,” it says. “Bedford Laboratories, Hospira Pharmaceuticals, Sandoz Pharmaceuticals, and Teva Pharmaceuticals were producing nearly one billion units of generic injectable products per year. Facilities at these companies are currently operating at about 700 million units per year. This decrease is a massive reduction in the industries' capacity to supply the nation with injectable medications.”
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Antidote: On Cystic Fibrosis treatments

Antidote: On Cystic Fibrosis treatments

Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.

The $3 generic and the $1,000 pill: pharma outsiders just don't get it

The $3 generic and the $1,000 pill: pharma ...

What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?

Leadership Exchange Uncut : The Agency-Client Relationship

Leadership Exchange Uncut : The Agency-Client Relationship

Click the above link to access MM&M's first Leadership Exchange Uncut e-book, "The Agency-Client Relationship"